June 19, 2013
Plandai: A Calming Product
It is no secret that obesity and poor diet remain increasing problems not only in the U.S., but throughout the industrialized world. Hypertension, or high blood pressure is a problem for the aging, the overweight, those who smoke or drink excessively, coffee drinkers, and those who consume too much salt, just to name a few. Referred to as the silent killer, high blood pressure affects 1 out of 3 American adults and can cause heart attacks, strokes, and kidney failure.
While there are numerous high blood pressure treatments, one thing to consider is the old adage: “An ounce of prevention is worth a pound of cure”, which may soon refer to Plandaí Biotechnology, Inc. (OTCQB - PLPL - $0.505 - Spec Buy). Plandaí develops highly bioavailable, phytonutrient extracts rich in anti-oxidant catechins like epigallocatechin gallate, or EGCG, which it intends to utilize to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions.
A number of studies have demonstrated that catechins found in green tea, especially ECGC, decreased the narrowing of blood vessels. Angiotensin converting enzyme (ACE), is an enzyme that leads to uncontrolled vascular constriction, causing blood pressure to rise. Drinking green tea can inhibit ACE activity and help reduce blood pressure.
For more information, refer to our previous PLPL Reports, Updates and Hot Topics by visiting www.GoldmanResearch.com
You Might Also Like
Senior Analyst: Robert Goldman
The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research report, update, article, or note is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.
This publication does not take into account the investment objectives, financial situation, or particular needs of any particular person. This report does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority.
ALL INFORMATION IN THIS REPORT IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.